#### Remarks

Claims 1-27 were originally filed with this application. In the present response, claims 1, 11, 12, 21, 22, and 27 have been amended, and claim 20 has been canceled. No new matter has been added by the amendments presented herein. Reconsideration of the present application in view of the above amendments and following remarks is respectfully requested.

#### **Specification**

Applicant has amended paragraph [0017] to correct an inadvertent error that remained unnoticed until the present response was being prepared. In particular, Applicant has corrected the concentration of commercially available hydrobromic acid from 48% or 62% by volume to 48% or 62% by weight. To support the amendment, Applicant has enclosed page 1139 from the 2005-2006 Adrich catalog, which provides a product (highlighted) that is 48 % by weight hydrobromic acid in water. Furthermore, Applicant submits that one of ordinary skill in the chemical arts would know that standard hydrobromic acid is sold in an aqueous solution, and its concentration is based on its percentage by weight, not volume.

In the outstanding Action, the Examiner required that the status of copending applications be updated in the specification. The Examiner noted that neither of the cited applications has actually issued. Accordingly, Applicant has amended the CROSS-REFERENCE TO RELATED APPLICATIONS section of the specification by deleting the portion referring to the patent number and issue date for copending patent application Serial No. 10/342,475, filed January 16, 2003 and by adding the serial number and filing date for the copending patent application entitled "BROMINATION OF HYDROXYAROMATIC COMPOUNDS". Paragraph [0018] was also amended to include the serial number and filing date for the copending application discussed therein. The attorney docket numbers have also been deleted from the CROSS-REFERENCE TO RELATED APPLICATIONS section and from paragraph [0018] of the specification.

### Rejection Under 35 U.S.C. § 112, Second Paragraph

Claim 20 and its dependent claim 21 were rejected under 35 U.S.C. § 112, second paragraph for being indefinite. It is the Examiner's opinion that the term "organic solvent" recited in claim 20 is ambiguous because "water" is included in the list of solvents recited in dependent claim 21, and water is not considered to be organic. As discussed below with respect to the prior art claim rejections, Applicant has canceled claim 20, which previously depended from claim 1, and has included the solvent limitation recited therein into claim 1. To overcome the § 112 rejection, amended claim 1 recites a "polar solvent" without including the word "organic". Support for the amendment to claim 1 comes from canceled claim 20, as well as from paragraph [0016] of the specification, which states that polar solvents may also be present in the reaction mixture. In addition, claim 21, which provides a list of polar solvents, has been amended to depend from claim 1.

Claim 22, which previously depended from claim 20, now canceled, has also been amended to be dependent from claim 1. In amended claim 22, Applicant has added the term "polar" before "solvent". Support for this amendment is found in paragraph [0016], which lists acetic acid as a polar solvent.

Claim 11 and its dependent claim 12 were also rejected under 35 U.S.C. § 112, second paragraph for being indefinite. It is the Examiner's opinion that the term "anhydrous" recited in claim 11 is ambiguous because claim 12 indicates that water is also present in the reaction mixture. To clarify the meaning of the claim and overcome the rejection, Applicant has amended claim 12 to recite that water is added to the anhydrous acidic medium recited in claim 11. Support for the amendment comes from paragraph [0023], which states that water may be added to the reaction mixture when the reaction is run under anhydrous conditions. For further clarification, Applicant has amended claim 11 to include the word "acidic" before "medium."

Based on the amendments discussed above, the rejection of claim 20 under 35 U.S.C. § 112, second paragraph is now moot, and the § 112 rejections of claims 11, 12, and 21 have been overcome.

## Rejections Under 35 U.S.C. §§ 102(b) and 103(a)

Claims 1, 2, 4-6, 11-20, 23, 26 and 27 were rejected under 35 U.S.C. § 102(b) as being anticipated by Neumann, *J. Chem. Soc. Chem Comm.* 1285-87 (1988). It is the Examiner's opinion that the reference teaches the process for preparing a brominated hydroxyaromatic compound recited in Applicant's claims.

Claims 1, 2, 4-6, 11-20, 23, 26 and 27 were also rejected under 35 U.S.C. § 103(a) as being obvious over Neumann. It is the Examiner's opinion that the use of other reactants not exemplified in the reference, as well as optimal reaction conditions, would be obvious to one of ordinary skill in the art.

To overcome the rejections, Applicant has amended independent claims 1 and 27 to require that the reaction mixture must also include a polar solvent. Support for the amendment comes from canceled claim 20 and paragraph [0016], which states that a polar solvent may also be present. This added limitation is neither taught nor suggested by Neumann.

In contrast, Neumann teaches away from Applicant's method, as recited in amended claims 1 and 27 by expressly requiring that the solvent be *nonpolar*. In particular, the abstract of the Neumann article states that "[s]elective bromination of phenol and its deriviatives . . . have been achieved by oxybromination . . . catalysed by . . . H<sub>5</sub>PMo<sub>10</sub>V<sub>2</sub>O<sub>40</sub>, which is dissolved in a *nonpolar* chlorohydrocarbon solvent . . . " (italics added). In addition, on page 1286 of the article, Neumann states at the bottom of the first column (before Table 1) and the top of the

USSN 10/650,567 Grigorii Lev Soloveichik Page 11 of 12

second column that "PMoV-2 in its acidic form is dissolved in nonpolar solvents, such as 1,2-dichloroethane." Furthermore, 1,2-dichloroethane is used as the solvent in the examples found in the journal article (see Tables 1 and 2, as well as the text).

Therefore, because the oxybromination process recited in Applicant's amended claims 1 and 27 requires that the reaction be conducted in a polar solvent, and because Neumann's reaction mixture requires a nonpolar chlorohydrocarbon solvent, Applicant's claims 1 and 27 can neither be anticipated by nor obvious over Neumann.

Likewise, claims 2, 4-6, 11-19, 23, and 26, which directly or indirectly depend from claim 1 and also require a polar solvent in the recited process, are also patentable over Neumann.

# Non-Statutory Double Patenting

Claims 1-6, 11, 13-23, 25, and 26 were provisionally rejected under the judicially-created doctrine of double patenting over claims 1-8 and 12-23 of copending Application Serial No. 10/650,566. In response to this rejection, Applicant submits herewith a Terminal Disclaimer to obviate the provisional double patenting rejection over the aforementioned copending application and fee therefore in compliance with 37 C.F.R. §§1.321(b) and (c). However, if additional fees are required for the filing of the present Terminal Disclaimer, the Commissioner is hereby authorized to charge those fees to Deposit Account No. 08-1935.

## Allowable Subject Matter

Claims 7-10 and 24, which directly or indirectly depend from claim 1, were objected to as being dependent upon a rejected claim base. Applicant submits that the provisional Terminal Disclaimer submitted herewith, as well as the amendment to claim 1, overcomes the rejection of claim 1. Therefore, there is no need to rewrite claims 7-10 and 24 into independent form, and claims 7-10 and 24 are therefore in condition for allowance as originally presented.

USSN 10/650,567 Grigorii Lev Soloveichik Page 12 of 12

There being no further outstanding issues, Applicant submits that claims 1-19 and 21-27 are now in condition for allowance, and Applicant respectfully requests the same. However, if the Examiner has any questions or further comments regarding the pending claims, he is invited to contact Applicant's representative at the number below.

Respectfully submitted,

Martha L. Boden

Attorney for Applicant

Reg. No. 39,115

Dated: September 21, 2005

HESLIN ROTHENBERG FARLEY & MESITI P.C.

5 Columbia Circle

Albany, New York 12203-5160

Telephone: (518)452-5600 Facsimile: (518)452-5579

H<sub>5</sub>NHNHC<sub>6</sub>H<sub>5</sub> FW 184.24 g amounts of azobenzene

or visit safcglobal.com

-50/53 S: 53-45-60-61 RTECS# MW2625000; TSCA glass btl 25 g

thylsilyloxy)-3,5,7,9,11,13,15-ypentacyclo[9,5,1,1<sup>2,9</sup>,1<sup>5,15</sup>,1<sup>7,13</sup>joctasiloxane, see thylsilyloxy)-Heptacyclopentyl substituted *Page* 2037

glass btl 100 g

30.40

84.20

vergeretrakistriphen	TOTO TOTO TO THE PERSON OF THE
脚級問題[18284-30-1] [(C <sub>6</sub> H <sub>6</sub> ) <sub>5</sub> P]。[	8hH FW 1157 00
Feser 11,255; 13,144	"" 144 (137.09 = 3% 19.
DXC/	4.46
R: 36/37/38 S: 26-37/39	140 to 146
THE PROPERTY AND ADDRESS OF THE PARTY AND ADDR	
835088-100MG 835088-1G	glass btl 100 mg 35.4
835088-1G	glass btl 1 g 159.0
Section of the sectio	
rinhenylphosphina Care	htelgoppen(t)/tiexame.p.90%;
[riphenylphosphine-Coppen [73636-93-0] [(C <sub>6</sub> H <sub>5</sub> ) <sub>3</sub> PCul	(I) hydride Hexamer
【淡淡淡染 <i>theser</i> 14.175: 15 166: 4c 1:	1l <sub>6</sub> FW 1961.04
R: 36/37/38 S: 26-36	, s
\$6.50g	
364975-1G	glass btl 1 g   34.50
364975-5G	glass btl 5 g 108.50
aydixindantin, 98%	1- 1- 3 100.30
5103-42-4] C <sub>18</sub> H <sub>10</sub> O <sub>6</sub>	A District
W 322.27	, , , , ,
Used in the determination of	HO HO
・ ・	OH ()
Merck 13,4796; Beil. 8,1,631	TON F
mp. · · · · · ·	400)
(H17309-5G	
H17309-25G	glass btl 5 g 63.80
M1203-23G	poly btl 25 g 211.00
lydrobenzamide 98%	P. S. W. S.
[92-29-5] C <sub>6</sub> H <sub>5</sub> CH(N=CHC <sub>6</sub> H	
Beil. 7,215	5) <sub>2</sub> FW 298.38
mp	
#SCA	102-to 105 °C
167649-50G	
The I	glass btl 50 g   48.30
lydrobenzom	5 752-25-20-20-20-20-20-20-20-20-20-20-20-20-20-
[492-70-6] C H CH/ON STATE	
	NC II
[492-70-6] C <sub>6</sub> H <sub>5</sub> CH(OH)CH(OI Merck 13,4798; Beil. 6,1004	H)C <sub>6</sub> H <sub>5</sub> FW 214.26
1, 1, 50, Dell. 0, 1004	
301426-250MG	
1, 1, 50, Dell. 0, 1004	glass btl 250 mg 33.30
301426-1G	glass btl 250 mg 33.30
301426-250MG 301426-1G (CR) (1) Hydrobenzolin 9997 52340-78-01 CL-H O SW	glass btl 250 mg 33.30 glass btl 1 g 91.00
301426-250MG 301426-1G 301426-1G 301426-1G 301426-1G 301426-1G 301426-1G 301426-1G 301426-1G 301426-1G	glass btl   250 mg   33.30   glass btl   1 g   91.00
301426-250MG 301426-1G 301426-1G (301426-1G (301426-1G (301426-1G (301426-1G) (30146-1G) (3014	glass btl 250 mg 33.30 glass btl 1g 91.00
301426-250MG   301426-1G   3	glass btl 250 mg 33.30 glass btl 1 g 91.00
301426-250MG 301426-1G 301426-1G [52340-78-0] C <sub>14</sub> H <sub>14</sub> O <sub>2</sub> FW ée: 99% (HPLC) (Diiral reagent   α <sub>1</sub> <sup>2</sup> +93°, c = ₹.5 in C <sub>2</sub> H <sub>5</sub> OH Beil. 6,III,5430	glass btl 250 mg 33.30 glass btl 1g 91.00
301426-250MG 301426-1G 301426-1G [\$2340-78-0] Ci <sub>1</sub> AH <sub>14</sub> O <sub>2</sub> FW ee: 99% (HPLC) Chiral reagent (a) <sup>26</sup> +93°, C = 2.5 in C <sub>2</sub> H <sub>5</sub> OH Beil. 6,III,5430	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H. OH   A P   I G
301426-250MG 301426-1G 301426-1G [52340-78-0] C <sub>14</sub> H <sub>14</sub> O <sub>2</sub> FW ée: 99% (HPLC) (Diiral reagent   α <sub>1</sub> <sup>2</sup> +93°, c = ₹.5 in C <sub>2</sub> H <sub>5</sub> OH Beil. 6,III,5430	glass btl 250 mg 33.30 glass btl 1 g 91.00
301426-250MG 301426-1G 301426-1G 32340-78-0) C <sub>14</sub> H <sub>14</sub> O <sub>2</sub> FW 6e: 99% (HPLC) Chiral reagent [α] <sup>28</sup> +93°, c = ₹.5 in C <sub>2</sub> H <sub>5</sub> OH Beil. 6,III,5430	glass btl 250 mg 33.30 glass btl 1 g 91.00 214.26 H OH H OH
301426-250MG 301426-1G  301426-1G  301426-1G  301426-1G  301426-1G  301426-1G  301426-1G  301426-1G  301426-250MG  301426-250M  301426-250MG	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H. OH   H. OH   H. OH   G. C.
301426-250MG 301426-1G  30144-1402  50146-1402  50	glass btl 250 mg 33.30 glass btl 1 g 91.00 214.26 H OH
301426-250MG 301426-1G  301426-1G  301426-1G  301426-1G  301426-1G  301426-1G  301426-1G  152340-78-0) CiaH <sub>14</sub> O <sub>2</sub> FW  6e: 99% (HPLC)  Gliral reagent  [αl <sub>2</sub> <sup>28</sup> +93°, c = ½,5 in C <sub>2</sub> H <sub>5</sub> OH  8ei. 6,III,5430  np	glass btl   250 mg   33.30   glass btl   1 g   91.00     214.26     H   OH   H   OH   H   OH   H   OH   H
301426-250MG   301426-1G   3	glass btl   250 mg   33.30   glass btl   1 g   91.00     214.26     H OH
301426-250MG   301426-1G   3	glass btl   250 mg   33.30   glass btl   1 g   91.00
301426-250MG   301426-1G   3	glass btl   250 mg   33.30   glass btl   1 g   91.00
301426-250MG   301426-1G	glass btl   250 mg   33.30   glass btl   1 g   91.00
301426-250MG 301426-1G  [301426-1G  [301426-1G  [301426-1G  [32340-78-0] $C_{14}H_{14}O_{2}$ FW see: 99% (HPLC)  Chiral reagent [ $c_{1}^{28}H_{14}H_{$	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H OH   H OH   H OH   Green
301426-250MG 301426-1G 3014460 30146-1G 301	glass btl   250 mg   33.30   glass btl   1 g   91.00     214.26     H OH   4   H OH   149 °C     Glass btl   5 g   39.80   glass btl   25 g   159.00     159.60     159.60     159.60     137 to 139 °C     137 to 139 °C     138.50   15 g   40.10     AC     138.50   15 g   40.10   AC     138.50   15 g   40.10     AC     138.50   15 g   40.10     AC     138.50   15 g   40.10     AC     138.50   15 g   40.10     AC     138.50   15 g   40.10
301426-250MG 301426-1G  301426-126  301426  301426-126  301426-126	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H OH   4   4   4   4   4   4   4   4   4
301426-250MG 301426-1G  30144140  30146-1G  3014	glass btl   250 mg   33.30   glass btl   1 g   91.00     214.26     H OH   H OH   H OH   H OH   Green   Gree
301426-250MG 301426-1G  301441400  301426-1G  301441400  301426-1G  301441400  301426-1G  301441400  301426-1G  3014141400  3014414	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H OH   H OH   H OH   Green
301426-250MG 301426-1G 301446-1G 301446-1G 30146-1G 301	glass btl   250 mg   33.30   glass btl   1 g   91.00     214.26     H OH   H OH   H OH   H OH   Green   Gree
301426-250MG   301426-1G	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H OH   H OH   H OH   Green
301426-250MG   301426-1G	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H OH   H OH   H OH   Green
301426-250MG   301426-1G	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H OH   4 A P OH   4 A P OH   4 A P OH   4 A P OH   6 A
301426-250MG   301426-1G	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H OH   H OH   H OH   Green
301426-250MG 301426-1G  30144-1402  3014-14	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H OH   H OH   Graph
301426-250MG 301426-1G 30144-1G 3014-1G 3014-1	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H. OH   44.10   Glass btl   25 g   159.00   TE   40.10   glass btl   25 g   158.50   47.10   60 °C   Glass btl   5 g   56.70   268   60 °C   Glass btl   5 g   56.70   268   60 °C   268
301426-250MG 301426-1G  30144-1402  3014-14	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H. OH   H. OH   H. OH   H. OH   G. O.
301426-250MG 301426-1G 30144-1G 3014-1G 3014-1	glass btl   250 mg   33.30   glass btl   1 g   91.00   214.26   H. OH   44.10   Glass btl   25 g   159.00   TE   40.10   glass btl   25 g   158.50   47.10   60 °C   Glass btl   5 g   56.70   268   60 °C   Glass btl   5 g   56.70   268   60 °C   268

								<b>=</b> .}	lyc	lrob	romi i
		Hydro	ome.	ववात्रक	50°4	(2)56.	18.89	(Anna Sec.)	S POST MARCH		The Contract of the Contract o
		110033	-10-61	HRr DA	100	01	-	-0.0			
14	6 ℃	6,282;	<b>13</b> ,4799 <b>10</b> ,200 queous I	; Fieser 1	1,450	<b>, 2</b> ,21	14; 3	3,154;	4,2	19; <b>5</b> ,:	332;
35	.40										
	.00	density	1.	49 g/mL mm Ha (2	25 °	C vn	) .		ວ່າ	0: /	
		vp R:	35-37	49 g/mL mm Hg (; 5: 26-45-7/	25 °( 9	:) vd	l			2.	8 (vs air)
		TraceSe	lectUltr	a, for tra	ace :	nalu			_		
						- K.	٠.			<0	5 ua/ka
	, <u>-</u>	Al		<0.5	10/10					<0.0	/ HODE
B.:	JU. 1	~3		< 0.5 /	101-	iviy	١			<n :<="" td=""><td>2 μg/kg 5 μg/kg</td></n>	2 μg/kg 5 μg/kg
		~u		. <0.1 u	$\alpha N_{\alpha}$	Mo	٠.			<n !<="" td=""><td></td></n>	
		DE		≤0.02 µ	4	140.	• •			, ≲1	µa∕ka
$\hat{\ }$	s [1	Bi	· · · · ·	≥0.02 μ ≤0.1 μ ≤0.01 μ	g/kg a/ka	OF.	٠.			. ≤0.2	μg/kg
_	.1.19	Ca		<1	2/2	D.	٠.			<11111	μg/kg μg/kg
•		-u		<0 0c	- 4			· · · ·		≤0.03 <0.03	μg/kg μg/kg
	- 6	r		≤0.05 μ <sub>2</sub> ≤0.05 μ <sub>2</sub>	g/kg	JC .				< 1	
	_19	.s		<0.02	14.0						
80				<0 1 mc	1/1/2	٠, ,				くいいつ	110/1/0
00	'	c		<0.5	1/4-	TI			٠.,	≲0.1 <0.02	μg/kg μg/kg
	, I U	a		<0.02 un	Na	v				<n 1<="" td=""><td>//</td></n>	//
	in			. ≤1 μg	/kg	Zn	٠			≤0.2	μα/kg
	172	3828-25	ONTE	. ≥1 μ9 ≤0.02 μ9	/kg	Zr	٠.	٠	٠.	≤0.1 <sub>1</sub>	μg/kg
۰Ć	:   -		OIVIL			-		250	) mL	37	6.30
	.										
0	][-										
	48 TS	wt. %	n wate	r, 99.99 <sub>+</sub>	%	:-				٠	
	[33	9245-5N	/L		<del>-</del>	glass	h+I			. •	
ند	33	9245-10	OML	~				5 r	nt/		.00
0	[33	9245-50	OML					500 n			.40
-					L					200	.00
ı	AC:	reagen	t. 48%								
1	47.0	0-49.0%	(ACS sn	ecificatio	n)						
1						ith co	lor-	rodad	can		
1	ign.	residue.	• • • •	ned botti \$0.002%≥ \$0.05%	6 S(	0 <sub>4</sub> 2- a	nd S	503 <sup>2-</sup> .	cap	<0.00:	3%
٠l	T.		.: • • •	≤0.002% 0.05%≥ 0.003%≥							
ı	PO <sub>4</sub>			≤0.003% ≤0.001%							
ı	· (*)	i			, ,,,	avy 11	ieta	is (as i	<i>ነ</i> ከ)		
1	TSCA	V: To a							• •	≤5 pp	om
l	438	065-5001	ML		TPV	С соа	ted	500 n	· ·		707
l	1	`		**************************************			i	20011	<u>'- </u>	51.5	0
ŀ	<u>ري. خ</u>	. 1			201		, i e , i e				
L	Ace:	;	••••				<u> </u>				
	1C5.	reagent,	48%				•				
1	SCA	,5,0,70 (2	rca shec	e as proc ification)		4380	65	•			
[	2442	60-100N	Ľ		Tflo	glass	110	0 ml			en
1	442	60-500M	L		fini	glass	150	0 ml		27.40	
	,				-	5.433		J 1711		44.70	נ
re	2001	nt grade	, 48%								-
T	CA	-									
TŞ	CA										
TŞ	CA	3-500ML			gla	ss btl	500	mL		23.00	ì